TScan Therapeutics, Inc.
TScan Therapeutics is a U.S.-based clinical-stage biotechnology company developing T cell receptor-engineered T cell, or TCR-T, therapies for cancer. Its platform centers on an ImmunoBank of therapeutic TCRs and a pipeline of product candidates for hematologic malignancies and solid tumors, with research, manufacturing, and development activities based in the United States.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueEngineered T cell therapies designed to recognize cancer targets through specific T cell receptors.
A proprietary repository of therapeutic TCRs used to build and expand the pipeline.
Partnered discovery and licensing arrangements that generate collaboration revenue.
Customers
TScan’s direct customers are primarily pharmaceutical and biotechnology partners that license or collaborate on TCR discovery and antigen identification programs. Its eventual end users are cancer patients treated through hospitals and oncology centers if product candidates reach commercialization. The company’s current business model is therefore split between partner-funded research relationships and a clinical development pipeline aimed at future therapeutic use.
Companies such as Amgen that fund research, receive data, and retain commercialization rights in partnered programs.
Smaller or specialized biotech firms that may license TCR discovery capabilities or collaborate on antigen identification.
Patients with hematologic or solid tumor cancers who would receive TCR-T therapies in clinical trials or after approval.
Clinical sites that enroll patients, administer cell therapy products, and support trial logistics.
Strategy
TScan’s strategy is to build a differentiated TCR-T pipeline using its ImmunoBank platform and to advance lead programs through clinical development. A key priority is internal manufacturing control, which supports process consistency, trial supply, and eventual commercial readiness. The company is also using collaborations and licensing to support research while it expands into additional hematologic and solid tumor targets.
Clinical proof-of-concept is needed to validate the platform and support later-stage development.
A broader TCR library increases the number of target/HLA combinations the company can pursue.
Cell therapy development depends on reproducible, scalable, and controlled manufacturing.
Geography
TScan is headquartered and operates primarily in the United States, where its corporate, research, and manufacturing activities are concentrated. Its manufacturing facility is in Waltham, Massachusetts, and its collaboration and clinical development work is also U.S.-based. The company’s commercial exposure is currently limited, but future expansion could extend beyond the U.S. if product candidates are approved or partnered internationally.
Risks
TScan faces the typical risks of a clinical-stage cell therapy company: uncertain clinical outcomes, regulatory review risk, and the need for substantial capital before any product revenue. It also competes in a crowded TCR and broader engineered T-cell market, where safety concerns, manufacturing complexity, and physician adoption can materially affect development and commercialization.
- Clinical development failureImpact: HighLikelihood: Medium
TCR-T candidates may not demonstrate sufficient safety or efficacy in trials.
Exposure: Lead programs TSC-101 and TSC-102 series
- Regulatory and safety scrutinyImpact: HighLikelihood: Medium
The FDA may require additional monitoring, labeling, or trial changes for engineered T-cell products.
Exposure: All TCR-T product candidates
- Financing dependenceImpact: HighLikelihood: Medium
The company has no approved therapies and must fund development through external capital and collaborations.
Exposure: Corporate liquidity and pipeline execution
- Competitive pressureImpact: MediumLikelihood: Medium
Multiple companies are developing TCR-based and other cell therapies for similar cancer indications.
Exposure: TCR space and broader cell therapy market
- Manufacturing complexityImpact: MediumLikelihood: Medium
Cell therapies require controlled, reproducible manufacturing and supply chain reliability.
Exposure: Clinical supply and future scale-up
Accounting
Judgemental itemsRevenue from the Amgen agreement depends on identifying performance obligations and recognizing them over the research term.
Impact: Affects reported revenue timing and comparability across quarters
Clinical trial, CRO, and manufacturing costs are estimated before invoices are finalized.
Impact: Can shift operating expense recognition between periods
Equity awards are a significant non-cash expense for a pre-commercial biotech.
Impact: Affects operating loss and diluted share calculations
Borrowings and related costs require amortization and classification judgments.
Impact: Influences interest expense and balance sheet presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
Immatics N.V.
IMTX · Biological Products, (No Diagnostic Substances)
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
Tvardi Therapeutics, Inc.
TVRD · Pharmaceutical Preparations
Tvardi Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapies for fibrosis-driven diseases and certain cancers.
TG Therapeutics, Inc
TGTX · Pharmaceutical Preparations
TG Therapeutics is a U.S.-based biopharmaceutical company focused on developing and commercializing treatments for B-cell diseases and related immune-mediated disorders.
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
Transcode Therapeutics, Inc.
RNAZ · Pharmaceutical Preparations
Last updated: 24/09/2026